What is the catalog number for Ozagrel?

The catalog number for Ozagrel is HY-B0428.

What sizes are available for Ozagrel?

Ozagrel is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does Ozagrel come in?

Ozagrel is available in 6 different pack sizes.

Ozagrel is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Ozagrel?

Ozagrel is manufactured by QuantiMol.

What is the estimated delivery time for Ozagrel?

Estimated delivery time for Ozagrel is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Ozagrel?

The safety data sheet for Ozagrel is available here: http://file.medchemexpress.com/batch_PDF/HY-B0428/Ozagrel-SDS-MedChemExpress.pdf.

Ozagrel

Ozagrel (OKY-046) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2) . Ozagrel can be used for the study of ischemic stroke, asthma and thromboembolic diseases[1][2][3][4][5].

Product Specifications

CAS Number

82571-53-7

Product Name Alternative

OKY-046

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Ozagrel.html

Purity

99.74

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O)/C=C/C1=CC=C(CN2C=CN=C2)C=C1

Molecular Formula

C13H12N2O2

Molecular Weight

228.25

Precautions

H302, H315, H319, H335

References & Citations

[1]Saito MS, et al. Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization. J Enzyme Inhib Med Chem. 2016 Dec;31 (6) :1591-601.|[2]Bhatia P, Singh N. Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. Fundam Clin Pharmacol. 2021 Aug;35 (4) :650-666.|[3]Bhatia P, Kaur G, Singh N. Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia. Vascul Pharmacol. 2021 Apr;137:106827.|[4]Ishitsuka Y, et al. A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. J Pharmacol Sci. 2009 Oct;111 (2) :211-5.|[5]Nakazawa M, et al. [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase]. Yakugaku Zasshi. 1994;114 (12) :911-33.